The subsidiary companies of Adiuvo Investments SA, which is a WSE-listed company focused on the commercialisation of innovative technologies in the life science sector, have signed agreements on EU funding of the research and development projects they conduct. Four projects of the combined estimated value of PLN 21.3 million will receive PLN 9.9 million of funding (on average 46.5% of the project value).
“The technologies developed by Adiuvo are distinguished by innovation and respond to the real needs of healthcare professionals and consumers, while following the global trends, in particular the growing need to focus on preventive measures rather than on the treatment of effects of diseases as well as on the participation of patients in the process of monitoring their health and on their active involvement in the treatment” emphasizes Anna Aranowska-Bablok, Member of the Management Board of Adiuvo Investments SA.
“As for the projects which have just received funding, we are going to finish them within 2-3 years. However, our portfolio also includes projects which are already at the stage of commercialisation and even monetized. For example, in the coming weeks, Airway Medix should receive cash from the first tranche of payment for the medical technology just sold, where the buyer is a large American company from the medical industry, and the total contract value exceeds PLN 44 million” adds Anna Aranowska-Bablok.
The EU financing relates to two Carocelle product lines and two MarMar projects. As far as the mentioned product lines are concerned, these are (1) Carocelle Deli-Caps (food supplements based on the Delligent technology, with highly bioactive polyphenols and vitamins) and (2) Carocelle Deli-Eye (food supplement in the Delligent technology, which protects the visual system thanks to the highly bioavailable lutein, DHA fatty acids and anthocyanins). On the other hand, the innovation of the currently developed MarMar products has been appreciated in (3) the development of a new generation of a food supplement which decreases and normalizes postprandial glycemia and insulinemia, and also decreases the body weight (a second generation of the already commercialized product under the name of Tribitor), and last but not least, (4) the development of a new innovative food supplement with properties for modifying the composition of the bacterial flora in the intestines, decreasing excessive body weight and improving the metabolic parameters in the formula delivered directly to the large intestine. The projects described above are planned to commence as early as in 2017.
***
Adiuvo Investments focuses on the selection, development, funding and commercialization of innovative technologies with a global reach, whereas their subject matter includes in particular (1) diseases management, monitoring of a healthy lifestyle and treatment with the application of mobile devices, and (2) food supplements and functional foods.
By ensuring the protection of intellectual property, technology validation in clinical trials in line with the pharmaceutical standard and acquiring marketing authorization certificates, Adiuvo is able to commercialize projects in various business models and on an international scale.
The research and development for the projects included in the portfolio is conducted, among others, in Great Britain, Israel, United States, Poland and Germany. This relates both to the location of research laboratories, which are usually run by the main inventors of specific products and technologies, and to the clinical trials carried out by renowned research centres.
Currently, the Adiuvo portfolio includes over 25 projects. Selected products of the Group are commercialized in over 20 markets worldwide. The first of the developed technologies has already been sold to a major entity operating within the industry, with its registered office in the USA – in August 2017, a subsidiary of Airway Medix signed a contract worth over PLN 44 million for the sale of technology known as CSS – the Closed Suction System (a closed cleaning system for maintaining hygiene of the endotracheal tube in patients ventilated mechanically).
Since 2015, Adiuvo Investments SA has been a company listed on the WSE main market. More information on the company is available at www.adiuvoinvestments.com.
